Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| Data from Phase III POLLUX Study of Daratumumab Published in The New England Journal of Medicine | 6 Oct 2016 |
| Grant of Warrants to Genmab Employees | 6 Oct 2016 |
| Genmab’s Financial Calendar for 2017 | 30 Sept 2016 |
| Major Shareholder Announcement | 28 Sept 2016 |
| Articles of Association for Genmab A/S | 28 Sept 2016 |